Healthcare investment bank Leerink Swann announced changes to their Institutional Equities leadership. The Firm has named Stephen Weiss as Senior Managing Director, Head of Institutional Equities, and promoted John Sullivan to the role of Director of Research.

Mr. Weiss, whose career in institutional equities spans more than 20 years, was previously Co-Head of Institutional Sales and a Senior Managing Director for Leerink Swann. Prior to joining the Firm, he was Co-founder and Managing Member of Short Hill Capital Partners, LLC. Additionally, Mr. Weiss was also Managing Director and Head of U.S. Cash Sales for Lehman Brothers.

Mr. Sullivan, who joined Leerink Swann in 2004 as an equity research analyst in the life sciences tools and consumables sector, has served as Managing Director, Life Sciences Tools and Services. He will continue to maintain his analyst responsibilities on an interim basis in addition to his responsibilities as Director of Research. Previously, Mr. Sullivan worked for Stephens Inc. as Senior Equity Research Analyst, Life Sciences.

“We are extremely excited to announce these two promotions to our Institutional Equities team,” said Jeffrey A. Leerink, Chairman and CEO of Leerink Swann. “Steve has been a valuable member of senior management at Leerink Swann, and John has been instrumental in expanding our equity research department by launching our tools and consumables’ coverage and providing our clients with trusted and coveted analysis. Their expanded leadership roles within our award-winning Institutional Equities platform will only enhance our ability to deliver the finest healthcare research, sales, and trading services on Wall Street.”

About Leerink Swann

Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, strategic advisory, and asset management services for institutional, life sciences, and high-net-worth clients. For the past seven years, Institutional Investor has named Leerink Swann Best of the Boutiques in several healthcare categories. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member of FINRA/SIPC.

Leerink Swann
Gregg DiPietro, 617-918-4601
Gregg.DiPietro@leerink.com
or
Schwartz Communications
Brian Bogie, 781-684-0770
Leerink@schwartz-pr.com

Comments

comments